GoAI
Get started
CervoMed Inc. logo

CervoMed Inc.

CRVO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.62

+$0.06 · +2.34%

Aug 21, 4:00 PM ET

CRVO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

29

Weakening

Sentiment

59

Mixed

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
John J. Alam
Listed since
May 23, 2008
Employees
15

Market position

Day range

Current $2.62

52-week range

Current $2.62

Open
$2.60
Previous close
$2.56
Volume
269.57K
0.05× average
Average volume
5.63M
Average daily volume
Market cap
24.26M USD
Beta
-4.31
Market reference 1
50-day average
$3.0598
-14.37% below average
200-day average
$4.8781
-46.29% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
63.19M USD
P/E (TTM)
-0.82×
P/B (TTM)
1.17×
P/S (TTM)
75.2×
EV / EBITDA
-2.34×
Earnings yield
-37.75%
Free cash flow yield
-32.83%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-9661.43%
Net margin
-9408.76%
Return on equity
-147.98%
Return on assets
-115.24%
Return on invested capital
-150.96%

Financial health

Debt / equity
0×
Current ratio
4.84×
Altman Z-score
-4.03
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−28.29M USD-55.23%

Net income

−26.97M USD-65.53%
Income trends across reported periods440.43K USD−10.01M USD−20.46M USD−30.91M USDOperating income, FY2021: −24.68M USDOperating income, FY2022: −3.48M USDOperating income, FY2023: −7.81M USDOperating income, FY2024: −18.23M USDOperating income, FY2025: −28.29M USDNet income, FY2021: −24.1M USDNet income, FY2022: −5.8M USDNet income, FY2023: −2.17M USDNet income, FY2024: −16.29M USDNet income, FY2025: −26.97M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −24.68M USD. Operating income FY2022 −3.48M USD. Operating income FY2023 −7.81M USD. Operating income FY2024 −18.23M USD. Operating income FY2025 −28.29M USD. Net income FY2021 −24.1M USD. Net income FY2022 −5.8M USD. Net income FY2023 −2.17M USD. Net income FY2024 −16.29M USD. Net income FY2025 −26.97M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development21.82M USD18.8M USD8.44M USD1.34M USD8.5M USD
Selling, general, and administrative10.48M USD9.17M USD6.52M USD2.14M USD7.45M USD
Operating expenses28.29M USD18.23M USD7.81M USD3.48M USD24.68M USD
Interest income1.34M USD1.94M USD219.43K USD62.23K USD137.49K USD
Interest expense———587 USD—
Depreciation and amortization————93.42K USD
Operating income−28.29M USD−18.23M USD−7.81M USD−3.48M USD−24.68M USD
Net income−26.97M USD−16.29M USD−2.17M USD−5.8M USD−24.1M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-8.72%
11 comparable reports
Latest EPS result
-0.64
Estimate -0.8 · Beat by 19.69%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.52-0.66-0.8-0.94Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual -0.8, estimate -0.67, surprise -19.40%, Miss. Q2 2025, reported May 12, 2025: actual -0.56, estimate -0.6, surprise +6.67%, Beat. Q3 2025, reported Aug 8, 2025: actual -0.7, estimate -0.615, surprise -13.87%, Miss. Q4 2025, reported Nov 7, 2025: actual -0.84, estimate -0.68, surprise -23.53%, Miss. Q1 2026, reported Mar 13, 2026: actual -0.88, estimate -0.79, surprise -11.39%, Miss. Q2 2026, reported May 18, 2026: actual -0.86, estimate -0.9, surprise +4.44%, Beat. Q3 2026, reported Aug 10, 2026: actual -0.64, estimate -0.797, surprise +19.69%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.61, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.33M1.56M780.39K5.53KQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual 2.16M USD, estimate 1.53M USD, surprise +40.75%, Beat. Q2 2025, reported May 12, 2025: actual 1.92M USD, estimate 1.72M USD, surprise +11.35%, Beat. Q3 2025, reported Aug 8, 2025: actual 1.76M USD, estimate 1.39M USD, surprise +26.83%, Beat. Q4 2025, reported Nov 7, 2025: actual 322.57K USD, estimate 1.21M USD, surprise -73.44%, Miss. Q1 2026, reported Mar 13, 2026: actual 6.51K USD, estimate 90.84K USD, surprise -92.83%, Miss. Q2 2026, reported May 18, 2026: actual —, estimate 71.43K USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 10, 2026: actual —, estimate 50K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 12, 2026: actual —, estimate 50K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.00

167.18% upside
Past 12 months12-month forecastHigh $7.00Average $7.00Low $7.00

Rating distribution

7 ratings
Strong buy00%
Buy7100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

7 institutions

CRVO news

globenewswire.com

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative…

Read source
globenewswire.com

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company…

Read source
globenewswire.com

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines

Read source
globenewswire.com

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

Read source
globenewswire.com

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference

Read source
globenewswire.com

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as…

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 17, 2023

2:3

Stock split

Effective Apr 19, 2022

1:50

Stock split

Effective Dec 14, 2018

1:15

Stock split

Effective Aug 19, 2016

1:10

Stock split

Effective Jun 30, 2014

1:100

Stock split

Effective Mar 10, 2014

1:100

CRVO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CRVO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
645.45K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
170.35K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
64.04K
Weight
0.00%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
8.4K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%

Continue in GoAI

Research CRVO

research.disclaimer